PL3638698T3 - Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2 - Google Patents

Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2

Info

Publication number
PL3638698T3
PL3638698T3 PL19701428T PL19701428T PL3638698T3 PL 3638698 T3 PL3638698 T3 PL 3638698T3 PL 19701428 T PL19701428 T PL 19701428T PL 19701428 T PL19701428 T PL 19701428T PL 3638698 T3 PL3638698 T3 PL 3638698T3
Authority
PL
Poland
Prior art keywords
antigen
binding fragments
tmprss2 antibodies
tmprss2
antibodies
Prior art date
Application number
PL19701428T
Other languages
English (en)
Inventor
Lisa Purcell
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3638698T3 publication Critical patent/PL3638698T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL19701428T 2018-01-26 2019-01-24 Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2 PL3638698T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622292P 2018-01-26 2018-01-26
EP19701428.5A EP3638698B1 (en) 2018-01-26 2019-01-24 Anti-tmprss2 antibodies and antigen-binding fragments
PCT/US2019/014978 WO2019147831A1 (en) 2018-01-26 2019-01-24 Anti-tmprss2 antibodies and antigen-binding fragments

Publications (1)

Publication Number Publication Date
PL3638698T3 true PL3638698T3 (pl) 2021-09-06

Family

ID=66102175

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19701428T PL3638698T3 (pl) 2018-01-26 2019-01-24 Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2

Country Status (26)

Country Link
US (3) US10941213B2 (pl)
EP (1) EP3638698B1 (pl)
JP (2) JP2021511058A (pl)
KR (2) KR20250133488A (pl)
CN (2) CN111936517B (pl)
AU (2) AU2019211406C1 (pl)
BR (1) BR112020015112A2 (pl)
CA (1) CA3089377A1 (pl)
CY (1) CY1124182T1 (pl)
DK (1) DK3638698T3 (pl)
ES (1) ES2864529T3 (pl)
HR (1) HRP20210876T1 (pl)
HU (1) HUE054403T2 (pl)
IL (2) IL312961A (pl)
LT (1) LT3638698T (pl)
MA (1) MA46731B1 (pl)
MD (1) MD3638698T2 (pl)
MX (2) MX2020007888A (pl)
PL (1) PL3638698T3 (pl)
PT (1) PT3638698T (pl)
RS (1) RS61825B1 (pl)
SG (1) SG11202006898TA (pl)
SI (1) SI3638698T1 (pl)
SM (1) SMT202100307T1 (pl)
WO (1) WO2019147831A1 (pl)
ZA (1) ZA202004494B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
BR112020015112A2 (pt) 2018-01-26 2021-04-06 Regeneron Pharmaceuticals, Inc. Anticorpos anti-tmprss2 e fragmentos que ligam antígenos
EP4034566A4 (en) 2019-09-23 2024-01-24 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CRTH2
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
WO2021163076A1 (en) * 2020-02-10 2021-08-19 Regeneron Pharmaceuticals, Inc. ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021211402A2 (en) * 2020-04-13 2021-10-21 Maddon Advisors Llc Ace2-targeted compositions and methods for treating covid-19
WO2021212101A1 (en) 2020-04-17 2021-10-21 Vyriad, Inc. Compositions for treating and/or preventing coronavirus infections
CA3180508A1 (en) 2020-04-17 2021-10-21 Regeneron Pharmaceuticals, Inc. Detection assays for coronavirus neutralizing antibodies
US20240043504A1 (en) 2020-05-26 2024-02-08 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
EP4161960A1 (en) 2020-06-03 2023-04-12 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
US12097212B2 (en) * 2020-06-08 2024-09-24 Brigham Young University Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
WO2021255217A1 (en) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
CN111986818A (zh) * 2020-08-21 2020-11-24 南通大学 一种基于tmprss2的新冠covid-19治疗药物筛选系统
WO2022051549A1 (en) * 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
WO2022115503A1 (en) 2020-11-25 2022-06-02 Dupont Nutrition Biosciences Aps Treatment and prevention of coronavirus infection
CN112538494A (zh) * 2020-12-08 2021-03-23 武汉华美生物工程有限公司 一种tmprss2突变体蛋白及其表达载体、表达工程菌和制备方法
WO2022133182A1 (en) * 2020-12-18 2022-06-23 Chan Zuckerberg Biohub, Inc. Method of treating coronavirus infection
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
WO2022204316A2 (en) 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
WO2023287875A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023199943A1 (ja) * 2022-04-12 2023-10-19 国立研究開発法人理化学研究所 コロナウイルス感染症を処置することに用いられる抗体
WO2023220712A1 (en) * 2022-05-13 2023-11-16 The Trustees Of Columbia University In The City Of New York Host proteases essential for parainfluenza spread in the human lung: potential targets for antiviral interventions
CN116003611B (zh) * 2022-08-17 2024-02-27 中南大学湘雅医院 抗tmprss2抗体及其用途
WO2024252183A1 (en) * 2023-06-08 2024-12-12 Institut Pasteur Single domain antibodies directed against human transmembrane- serine protease 2 (tmprss2)
WO2025072792A1 (en) * 2023-09-28 2025-04-03 The Regents Of The University Of California Methods for identifying and treating diseases characterized by allele specific expression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE429643T1 (de) * 2000-07-12 2009-05-15 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8354508B2 (en) 2006-07-21 2013-01-15 Diadexus, Inc. PRO115 antibody compositions and methods of use
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
MX2010012518A (es) 2008-05-16 2010-12-06 Ablynx Nv Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos.
HUE042531T2 (hu) * 2012-01-31 2019-07-29 Regeneron Pharma ASIC1-ellenes antitestek és alkalmazásaik
KR20150008383A (ko) * 2012-04-16 2015-01-22 리제너론 파아마슈티컬스, 인크. 세린 프로테아제 억제제의 투여에 의한 인플루엔자 바이러스 감염의 치료 또는 예방 방법
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
PT3422845T (pt) 2016-02-29 2021-08-26 Regeneron Pharma Roedores com um gene tmprss humanizado
WO2018175749A2 (en) * 2017-03-22 2018-09-27 Children's Medical Center Corporation Lrp1 binding agents and uses thereof
BR112020015112A2 (pt) 2018-01-26 2021-04-06 Regeneron Pharmaceuticals, Inc. Anticorpos anti-tmprss2 e fragmentos que ligam antígenos

Also Published As

Publication number Publication date
WO2019147831A1 (en) 2019-08-01
MA46731A (fr) 2020-04-22
MD3638698T2 (ro) 2021-07-31
AU2019211406A1 (en) 2020-08-13
LT3638698T (lt) 2021-04-12
CN111936517B (zh) 2025-04-18
CA3089377A1 (en) 2019-08-01
SG11202006898TA (en) 2020-08-28
MA46731B1 (fr) 2021-06-30
CN120290578A (zh) 2025-07-11
IL276164B2 (en) 2024-11-01
US12065506B2 (en) 2024-08-20
SI3638698T1 (sl) 2021-07-30
KR20250133488A (ko) 2025-09-05
CN111936517A (zh) 2020-11-13
MX2024006462A (es) 2024-06-11
EP3638698A1 (en) 2020-04-22
CY1124182T1 (el) 2022-05-27
ZA202004494B (en) 2022-05-25
JP2024009962A (ja) 2024-01-23
IL312961A (en) 2024-07-01
US20220081489A9 (en) 2022-03-17
ES2864529T3 (es) 2021-10-14
BR112020015112A2 (pt) 2021-04-06
US11603413B2 (en) 2023-03-14
IL276164B1 (en) 2024-07-01
AU2025204183A1 (en) 2025-06-26
KR20200115576A (ko) 2020-10-07
SMT202100307T1 (it) 2021-07-12
EP3638698B1 (en) 2021-03-03
JP2021511058A (ja) 2021-05-06
IL276164A (en) 2020-09-30
DK3638698T3 (da) 2021-04-26
HUE054403T2 (hu) 2021-09-28
AU2019211406C1 (en) 2025-07-17
HRP20210876T1 (hr) 2021-07-09
US20190300625A1 (en) 2019-10-03
US20230265216A1 (en) 2023-08-24
US10941213B2 (en) 2021-03-09
PT3638698T (pt) 2021-04-06
AU2019211406B2 (en) 2025-03-06
MX2020007888A (es) 2020-09-07
RS61825B1 (sr) 2021-06-30
US20210230303A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
PL3638698T3 (pl) Przeciwciała i fragmenty wiążące antygen anty-TMPRSS2
IL269593A (en) Anti-ILT4 antibodies and antigen-binding fragments
PT3802608T (pt) Anticorpos anti-cd3 e utilizações destes
EP3889179A4 (en) Bispecific antibody and use thereof
EP3904386A4 (en) Antibody and use thereof
EP4008730A4 (en) BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
KR102763158B9 (ko) 최적화된 항tl1a 항체
EP3797124A4 (en) ANTI-RO1 ANTIBODIES AND ITS USE
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP3802612A4 (en) Anti-b7-h3 antibody and use thereof
IL289354A (en) Anti-cd154 antibodies and uses thereof
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
IL280757A (en) Monoclonal antibodies against human tim-3
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND ITS USES
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP3763743A4 (en) BISPECIFIC ANTIBODY
EP3487518A4 (en) HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
EP3947461A4 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
EP3790586A4 (en) Anti-dll3 antibodies and uses thereof
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
EP3768724A4 (en) NEW ANTI-PD-1 ANTIBODIES
IL280281A (en) Anti-cd40 antibodies and uses thereof
IL281594A (en) Anti-klrg1 antibodies